


Management of hyperglycaemia* in acute coronary syndrome (ACS)



Box 2. Commonly used diabetes medications review (for guidance only).
Please consult BNF / local guidance / diabetes specialist team if patient taking combination drugs.

If heart failure (NYHA I – IV)	Stop Pioglitazone (regardless of eGFR)													
	Met	SU	Pio	DPP4				SGLT2			GLP1 analogue			Ins
				Linagliptin	Saxagliptin	Sitagliptin	Vildagliptin	Canagliflozin	Dapagliflozin	Empagliflozin	Exenatide	Liraglutide	Lixisenatide	
eGFR >60														
eGFR 45-60														
eGFR 30-45														
eGFR 15-30														
eGFR <15														

Met-Metformin, SU-sulphonylurea, Pioglitazone, DPP4 inhibitors-dipeptidyl peptidase 4 inhibitors, SGLT2-sodium glucose uptake transporter 2, GLP1-Glucagon like peptide analogue, Ins-Insulin

Management of Hyperglycaemia in Acute Coronary Syndrome (ACS)

Date		Version
October 2020		3.1
Accountabilities		
Author	Diabetes/Endocrine consultants Dr Ioannis Dimitropoulos, Dr Aftab Aziz and DSN Corrina Newton	
Reviewed by (Group)	Diabetes MDT	
Approved by (Lead)	Dr Ioannis Dimitropoulos, Dr Aftab Aziz	
Links to other documents		
Version History		
1.0	July 2012	Guideline introduced
2.0	November 2017	Guideline updated
3.0	December 2018	Guideline updated
3.1	October 2020	Guideline reviewed – no changes
Last Approval		Due for Review
October 2020		October 2022